Aspire Biopharma Holdings, Inc.
No enriched coverage for $ASBP in the last 7 days.
No SEC Form 4 filings for $ASBP in the last 30 days.
See all $ASBP insider activity →Aspire Biopharma Holdings, Inc. (ASBP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.3 3 ex10-3.htm EX-10.3 Exhibit 10.3 SECURED CONVERTIBLE PROMISSORY NOTE PURCHASE AGREEMENT THIS SECURED CONVERTIBLE PROMISSORY NOTE PURCHASE AGREEMENT (this “ Agreement ”), dated as of August 6, 2026, is entered into by and among Aspire Biopharma Holdings, Inc., a Delaware
Aspire Biopharma Holdings (NASDAQ:ASBP) said it completed its acquisition of Dura Driver Control Systems (DCS), buying 100% for about $30.0 million cash. Aspire also arranged a $22.5 million senior secured revolving credit facility to fund the deal. DCS reported 2025 revenue of $209.5 million and Adjusted EBITDA of $22.3 million.
Aspire Biopharma Holdings Inc. (NASDAQ:ASBP) said it completed a $30 million cash acquisition of Dura Driver Control Systems (DCS), gaining 100% ownership. Aspire also entered a $22.5 million senior secured revolving credit facility to fund the deal. DCS reported $209.5M audited 2025 revenue and $22.3M adjusted EBITDA. ASBP shares were down 0.39% to $7.70 premarket.
Recent ASBP coverage spans corporate actions, mergers & acquisitions and market movers.
The filing signals a dilutive financing structure (convertible notes) with an investor option to convert upon an event of default, increasing near-term balance-sheet and dilution risk.
Deal close and new financing are likely to re-rate Aspire’s near-term cash-flow and profitability narrative, but execution and integration risk remain.
The DCS buyout is a diversification and scale step, funded with cash plus a new $22.5 million revolving credit facility.
A stated NDA filing plan is a forward-looking regulatory catalyst that can improve probability-weighted valuation.
Approval clears corporate governance steps needed for warrant exercises and related share issuance/terms adjustments.
alphai scores every news story that mentions ASBP with an AI model for sentiment and relevance, and aggregates insider trades from Aspire Biopharma Holdings, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Aspire Biopharma Holdings, Inc. (ASBP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.3 3 ex10-3.htm EX-10.3 Exhibit 10.3 SECURED CONVERTIBLE PROMISSORY NOTE PURCHASE AGREEMENT THIS SECURED CONVERTIBLE PROMISSORY NOTE PURCHASE AGREEMENT (this “ Agreement ”), dated as of August 6, 2026, is entered into by and among Aspire Biopharma Holdings, Inc., a Delaware
6 min readAspire Biopharma Holdings (NASDAQ:ASBP) said it completed its acquisition of Dura Driver Control Systems (DCS), buying 100% for about $30.0 million cash. Aspire also arranged a $22.5 million senior secured revolving credit facility to fund the deal. DCS reported 2025 revenue of $209.5 million and Adjusted EBITDA of $22.3 million.
6 min readAspire Biopharma Holdings Inc. (NASDAQ:ASBP) said it completed a $30 million cash acquisition of Dura Driver Control Systems (DCS), gaining 100% ownership. Aspire also entered a $22.5 million senior secured revolving credit facility to fund the deal. DCS reported $209.5M audited 2025 revenue and $22.3M adjusted EBITDA. ASBP shares were down 0.39% to $7.70 premarket.
4 min readBiotech stocks rose as several companies issued updates. Wellgistics Health (WGRX) completed a rebrand to DataMEDS AI and will trade as MEDS; it reported Q1 2026 revenue of $0.929M and expects $1.775M in Q2. Dyadic (DYAI) saw a major shareholder sell. Palvella (PVLA) submitted the first NDA module for QTORIN. Sol-Gel (SLGL) expects SGT-610 Phase 3 data in Q4 2026.
6 min readAspire Biopharma Holdings, Inc. (ASBP) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001847345 0001847345 2026-06-16 2026-06-16 0001847345 ASBP:CommonStockParValue0.0001PerShareMember 2026-06-16 2026-06-16 0001847345 ASBP:WarrantsEachExercisableForOneShareOfCommonStockMember 2026-06-16 2026-06-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STA
3 min readAspire Biopharma Holdings, Inc. (ASBP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 PURCHASE AGREEMENT between FireFish TopCo, LLC and Aspire Biopharma Holdings, Inc. Dated as of June 10, 2026 TABLE OF CONTENTS Article I DEFINITIONS AND INTERPRETATIONS 1 Section 1.01. Definitions 1 Article II CLOSING 1 Section 2.01. Clos
6 min readBiotech stocks rose Monday as investors reacted to clinical and regulatory updates. Tango Therapeutics (TNGX) jumped 52.97% after initial Phase 1/2 pancreatic cancer data showed 90% 6-month PFS; Alvotech (ALVO) gained 19.77% as the FDA accepted its Entyvio interchangeable biosimilar AVT16; Zevra (ZVRA) rose 13.95% on an Orange Book listing for MIPLYFFA.
7 min readSciSparc (SPRC) shares rose ~140% after its TSX Venture subsidiary received conditional approval to buy ~54% of private Israeli CliniQuantum for 56.6M NeuroThera shares (~$9.46M). Co-Diagnostics (CODX) gained ~53% for a third day amid Ebola PCR assay progress. Akari (AKTX) jumped ~38% on ASCO abstract acceptance and new KRAS-mutant synergy data; Outlook (OTLK) rose ~26% ahead of a June FDA resubmission.
6 min readAspire Biopharma (Nasdaq: ASBP) CEO Kraig Higginson sent a shareholder letter outlining plans for 2026. The board authorized a $5.0 million share repurchase after a preferred-stock private placement generated about $21.0 million net proceeds and the company regained Nasdaq equity compliance. Aspire said it plans to file an NDA for its high-dose sublingual aspirin via the 505(b)(2) pathway by end-2026. It also proposed acquiring Dura Driver Control Systems for $30 million cash; DCS reported 2025
4 min readAspire Biopharma Holdings (ASBP) will implement a 1-for-30 reverse stock split on May 11, 2026. This action will consolidate shares, reduce the total share count, and assign a new CUSIP number while retaining the existing ticker symbol. The company, operating in the biopharmaceutical sector, aims to manage its market position through this capital markets action.
2 min read
